Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)
This study is testing a new drug called LP-300 combined with standard chemotherapy medications to see if it works better than chemotherapy alone. It focuses specifically on never-smokers with advanced lung adenocarcinoma whose cancer has returned after targeted treatments.
You may be able to join if you have advanced lung adenocarcinoma, have never been a smoker, and your cancer has grown or stopped responding to targeted TKI pills. Certain other health history and genetic marker requirements also apply.
Participants will receive the experimental drug LP-300 along with standard chemotherapy drugs called carboplatin and pemetrexed. Doctors will closely monitor your health, how you feel, and how your cancer responds to the treatment.
This study is currently recruiting patients at multiple medical locations in California, United States. Your care team will guide you on the exact schedule and clinic visits required.
- 1Tests the new drug LP-300 with standard chemotherapy
- 2Designed specifically for never-smokers with advanced lung cancer
- 3Currently recruiting patients at study locations in California
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.